deltatrials
Completed NA NCT00149708

Consequence of Lifetime Isolated Growth Hormone Deficiency

Sponsor: Genentech, Inc.

Conditions Growth Hormone Deficiency
Interventions growth hormone administration for 6 months
Updated 5 times since 2017 Last updated: Jun 13, 2010 Started: Sep 30, 2005 Primary completion: Dec 31, 2009 Completion: Dec 31, 2009

Listed as NCT00149708, this NA trial focuses on Growth Hormone Deficiency and remains completed. Sponsored by Genentech, Inc., it has been updated 5 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  4. Jun 2018 — Jan 2021 [monthly]

    Completed NA

  5. Jan 2017 — Jun 2018 [monthly]

    Completed NA

    First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genentech, Inc.
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Data source: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Aracaju, Brazil